Medicinal Chemistry Services
We routinely apply computer sciences in computational chemistry approaches and apply methods for structure-based drug design, in case structural data of the target…
High quality library design requires chemical creativity and profound synthesis knowledge to achieve the highest possible molecular diversity. Our efficient production…
Looking for medicinal chemistry services for your drug discovery?
Comprehensive medicinal chemistry services
- 20 years of excellence in custom synthesis and medicinal chemistry research ensure molecules with optimised properties and patentability.
- Dedicated group for scaffold design and synthesis of compound libraries to gain quick access to a large number of compounds for SAR evaluation.
- Our proprietary project management software Ìǹûvlog¹ÙÍøÍøÒ³°æGate® allows our scientists and clients to jointly analyse data and thereby provides support for informed selection of the next steps in the project.
- Our own multi-purpose pilot plant facility in Asia for large-scale syntheses grants us access to a broad supplier network for building blocks, etc.
Custom Synthesis
Indications and Gene Families
Looks interesting?
As a leading CRO in Europe, Ìǹûvlog¹ÙÍøÍøÒ³°æ provides comprehensive drug discovery chemistry services for large Pharma and Biotech corporations as well as for Research Institutes and Academia
Frequently Asked Questions
Ìǹûvlog¹ÙÍøÍøÒ³°æ provides medicinal chemistry support from hit validation and hit expansion through hit-to-lead, lead optimisation and candidate selection. Services include compound design and synthesis, structure-activity relationship exploration, scaffold modification, parallel synthesis, compound-library production and the optimisation of potency, selectivity, physicochemical properties, ADME behaviour and synthetic tractability.
Ìǹûvlog¹ÙÍøÍøÒ³°æ follows a multidimensional optimisation approach rather than optimising one property at a time. Potency, selectivity, solubility, permeability, metabolic stability, safety-related liabilities, intellectual-property position and synthetic accessibility can be evaluated in parallel. This helps identify optimisation conflicts earlier and reduces the risk of advancing a potent compound series that later fails because of another property.
Ìǹûvlog¹ÙÍøÍøÒ³°æ combines medicinal chemistry with structure-based and ligand-based computational methods. Depending on the available data, the team may use virtual screening, molecular modelling, pharmacophore approaches, scaffold hopping, QSAR analysis and multiparameter design to prioritise compounds. Computational recommendations are evaluated alongside experimental synthesis, biological profiling and medicinal chemistry judgement.